(S)-(2'-cyclopentyl-5'-hydroxy-4'-isopropyl-5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinoline]-3'-yl)(4-(trifluoromethyl)phenyl)methanone | 507478-21-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-(2'-cyclopentyl-5'-hydroxy-4'-isopropyl-5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinoline]-3'-yl)(4-(trifluoromethyl)phenyl)methanone
• 英文别名: (S)-(2'-cyclopentyl-5'-hydroxy-4'-isopropyl-5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinolin]-3'-yl)(4-(trifluoromethyl)phenyl)methanone；[(5S)-2-cyclopentyl-5-hydroxy-4-propan-2-ylspiro[6,8-dihydro-5H-quinoline-7,1'-cyclobutane]-3-yl]-[4-(trifluoromethyl)phenyl]methanone
• CAS: 507478-21-9
• 化学式: C₂₈H₃₂F₃NO₂
• 分子量: 471.563
• InChiKey: SNJLJLHEGUOVAN-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-Cyclopentyl-4-propan-2-yl-3-[4-(trifluoromethyl)benzoyl]spiro[6,8-dihydroquinoline-7,1'-cyclobutane]-5-one 在 硼烷-N,N-二乙基苯胺 、 (1R,2S)-1-氨基-2-茚醇 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 (S)-(2'-cyclopentyl-5'-hydroxy-4'-isopropyl-5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinoline]-3'-yl)(4-(trifluoromethyl)phenyl)methanone
  参考文献：
  名称：

  Novel tetrahydrochinoline derived CETP inhibitors

  摘要：

  In the course of our efforts to identify orally active cholesteryl ester transfer protein (CETP) inhibitors, we have continued to explore tetrahydrochinoline derivatives. Based on BAY 19-4789 structural modifications led to the discovery of novel cycloalkyl substituted compounds. Thus, example 11b is a highly potent CETP inhibitor both in vitro and in vivo in transgenic mice with favourable pharmacokinetic properties for clinical development. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.071

文献信息

• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：DalCor Pharma UK Ltd Leatherhead, Zug Branch

  公开号：EP3833336A1

  公开（公告）日：2021-06-16
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• [EN] METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS<br/>[FR] MÉTHODES DE TRAITEMENT OU DE PRÉVENTION DE TROUBLES CARDIOVASCULAIRES ET D'ABAISSEMENT DU RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES
  申请人：DALCOR PHARMA UK LTD STOCKPORT ZUG BRANCH

  公开号：WO2019043018A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• [EN] METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES<br/>[FR] PROCÉDÉS POUR RETARDER L'APPARITION D'UN NOUVEAU DEBUT DE DIABÈTE DE TYPE 2 DE TYPE 2 ET POUR RALENTIR LA PROGRESSION ET TRAITER LE DIABÈTE DE TYPE 2
  申请人：DALCOR PHARMA UK LTD LEATHERHEAD ZUG BRANCH

  公开号：WO2020030814A1

  公开（公告）日：2020-02-13

  The invention provides compositions and methods useful for delaying occurrence of new- onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.
• Novel tetrahydrochinoline derived CETP inhibitors
  作者：Carsten Schmeck、Heike Gielen-Haertwig、Alexandros Vakalopoulos、Hilmar Bischoff、Volkhart Li、Gabriele Wirtz、Olaf Weber

  DOI：10.1016/j.bmcl.2010.01.071

  日期：2010.3

  In the course of our efforts to identify orally active cholesteryl ester transfer protein (CETP) inhibitors, we have continued to explore tetrahydrochinoline derivatives. Based on BAY 19-4789 structural modifications led to the discovery of novel cycloalkyl substituted compounds. Thus, example 11b is a highly potent CETP inhibitor both in vitro and in vivo in transgenic mice with favourable pharmacokinetic properties for clinical development. (C) 2010 Elsevier Ltd. All rights reserved.